Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS)

被引：2
|
作者：
Candoni, A.
Raza, A.
Galili, N.
Simeone, E.
Buttignol, S.
Silvestri, F.
Fanin, R.
机构：
[1] Univ Hosp, Div Hematol Bone Marrow Transplantat, Udine, Italy
[2] Univ Massachusetts, Med Ctr, Amherst, MA 01003 USA
来源：
LEUKEMIA RESEARCH | 2007年 / 31卷
关键词：
D O I：
10.1016/S0145-2126(07)70214-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [41] BIOSIMILAR EPOETIN ZETA FOR THE TREATMENT OF ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
    Pelizzari, A.
    Ferrero, D.
    Molteni, A.
    Allione, B.
    Mezzabotta, M.
    Clavio, M.
    Borlenghi, E.
    Rossi, G.
    Masiera, E.
    Santini, V.
    LEUKEMIA RESEARCH, 2015, 39 : S56 - S57
  • [42] Treatment and outcome of 23 paediatric patients with myelodysplastic syndromes (MDS)
    Polychronopoulou, S
    Panagiotou, JP
    Papadakis, V
    Parcharidou, A
    Psiachou, H
    Mavrou, A
    Haidas, S
    LEUKEMIA, 2000, 14 (05) : 969 - 969
  • [43] Myelodysplastic syndromes (MDS): An international practice and treatment survey.
    List, AF
    BLOOD, 2005, 106 (11) : 712A - 712A
  • [44] Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid
    Kuendgen, A
    Strupp, C
    Aivado, M
    Bernhardt, A
    Hildebrandt, B
    Haas, R
    Germing, U
    Gattermann, N
    BLOOD, 2004, 104 (05) : 1266 - 1269
  • [45] TREATMENT OF ASCARIASIS WITH PIPERAZINE CITRATE ALONE AND IN COMBINATION WITH OTHER ANTHELMINTIC AGENTS
    HOEKENGA, MT
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1956, 5 (02): : 382 - 382
  • [46] Incorporating novel agents in the treatment of myelodysplastic syndromes
    Anargyrou, Konstantinos
    Vassilakopoulos, Theodoros P.
    Angelopoulou, Maria K.
    Terpos, Evangelos
    LEUKEMIA RESEARCH, 2010, 34 (01) : 6 - 17
  • [47] Novel therapeutic agents for the treatment of myelodysplastic syndromes
    Cheson, BD
    Zwiebel, JA
    Dancey, J
    Murgo, A
    SEMINARS IN ONCOLOGY, 2000, 27 (05) : 560 - 577
  • [48] DIFFERENTIATING AGENTS IN THE TREATMENT OF LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
    DEGOS, L
    LEUKEMIA RESEARCH, 1990, 14 (08) : 731 - 733
  • [49] Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)
    Cortes, Jorge
    Yang, Jay
    Lee, Sangmin
    Dinner, Shira N.
    Wang, Eunice S.
    Baer, Maria R.
    Donnellan, William B.
    Watts, Justin M.
    BLOOD, 2023, 142
  • [50] RIGOSERTIB IN COMBINATION WITH AZACITIDINE MODULATES EPIGENETIC PATHWAYS AND CAN OVERCOME CLINICAL RESISTANCE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES (MDS)
    Chaurasia, P.
    Isoda, F.
    Navada, S.
    Odchimar-Reissig, R.
    Demakos, E. P.
    Reddy, E. P.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2017, 55 : S121 - S121
12345